

PRESS RELEASE

Source: Mentor Capital, Inc.

Mentor Capital, Inc. Acquires 20% of Cutting Edge Cancer Immunotherapy Company: Quantum Immunologics, Inc.

(For Immediate Release, July 10, 2009)

SAN DIEGO, Mentor Capital, Inc. (Pink Sheets: MNTR) is pleased to announce that it is providing equity funding to support Quantum Immunologics, Inc. (QI) to complete their FDA authorized Phase I/II trials on metastatic breast cancer, which are now underway (NCT00879489). QI holds exclusive license to patents that pertain to certain therapeutic and diagnostic applications of the Oncofetal Antigen (OFA), a universal marker found on all tested cancer lines but not found in normal tissues. The current QI clinical approach is to externally process and sensitize dendritic cells from the patient's own blood to recognize the OFA in their breast cancers as a marker for diseased tissue. The sensitized dendritic cells are then re-injected into the patient to stimulate their body's own immune system to attack the cancerous cells in an effort to eradicate or stabilize the patient's disease. Dendreon (DNDN) utilizes a similar dendritic immunotherapy approach, but focuses on a prostate-specific protein, through its Provenge product.

In addition to providing \$2.2 Million in funding to help support the FDA trials through approximately February 2010, Mentor Capital has agreed to assist QI in funding future strategic stock or cash acquisitions. Mentor will also stand by as a preferred funding source for QI during later stage or additional trials. In exchange for this financial support, Mentor Capital has received common stock in QI reflecting a carried interest of 20%. At the current private placement price for the QI shares, the acquisition of the QI position increases Mentor Capital assets per share by \$3.74 per share.

The Oncofetal Antigen – Immature Laminin Receptor patents are a product of 20 years and \$30 Million of research at The University of South Alabama Medical & Science Foundation and were primarily funded by the National Institute of Health's National Cancer Institute. The complete Quantum Immunologics corporate story, including a summarizing video of the QI breast cancer treatment methodology that is entering FDA trials, may be found at their company web site:

www.QuantumImmunologics.com. Comprehensive information on Mentor Capital, including capital structure detail, can be found at: www.MentorCapital.com. Level II quotes, news, financial information and trading charts may be referenced at www.PinkSheets.com under the trading symbol MNTR.

Forward Looking Statements, Safe Harbor and Risk Descriptions are Incorporated by Reference from the MNTR Company Web Site above.

For further information contact:

Chet Billingsley, CEO
Mentor Capital, Inc.
P.O. Box 1709
Ramona, CA 92065

(760) 788-4700